Prostate Cancer Early Detection, Version 2.2015

• DOI: 10.6004/jnccn.2015.0181
• Publication Date: 2017-04-14T12:06:28Z
• Authors: Peter R. Carroll; J. Kellogg Parsons; Gerald Andriole; Robert R. Bahnson; Daniel A. Barocas; Erik P. Castle; William J. Catalona; Douglas M. Dahl; John W. Davis; Jonathan I. Epstein; Ruth B. Etzioni; Thomas Farrington; George P. Hemstreet; Mark H. Kawachi; Paul H. Lange; Kevin R. Loughlin; William Lowrance; Paul Maroni; James Mohler; Todd M. Morgan; Robert B. Nadler; Michael Poch; Chuck Scales; Terrence M. Shane...; Marc C. Smaldone; Geoffrey Sonn; Preston Sprenke; Andrew J. Vickers; Robert Wake; Dorothy A. Shead; Deborah Freedman-...
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

Prostate cancer represents a spectrum of disease that ranges from nonaggressive, slow-growing disease that may not require treatment to aggressive, fast-growing disease that does. The NCCN Guidelines for Prostate Cancer Early Detection provide a set of sequential recommendations detailing a screening and evaluation strategy for maximizing the detection of prostate cancer that is potentially curable and that, if left undetected, represents a risk to the patient. The guidelines were developed for healthy men who have elected to participate in the early detection of prostate cancer, and they focus on minimizing unnecessary procedures and limiting the detection of indolent disease.